- Home
- GECC vs QNCX Comparison
GECC vs QNCX Comparison
Compare GECC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- QNCX
- Stock Information
- Founded
- GECC 2016
- QNCX 2012
- Country
- GECC United States
- QNCX United States
- Employees
- GECC N/A
- QNCX N/A
- Industry
- GECC Finance: Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- QNCX Health Care
- Exchange
- GECC Nasdaq
- QNCX Nasdaq
- Market Cap
- GECC 122.4M
- QNCX 47.7M
- IPO Year
- GECC N/A
- QNCX 2019
- Fundamental
- Price
- GECC $10.95
- QNCX $1.60
- Analyst Decision
- GECC
- QNCX Strong Buy
- Analyst Count
- GECC 0
- QNCX 5
- Target Price
- GECC N/A
- QNCX $8.00
- AVG Volume (30 Days)
- GECC 22.8K
- QNCX 344.4K
- Earning Date
- GECC 07-31-2025
- QNCX 08-12-2025
- Dividend Yield
- GECC 14.10%
- QNCX N/A
- EPS Growth
- GECC N/A
- QNCX N/A
- EPS
- GECC 0.42
- QNCX N/A
- Revenue
- GECC $42,909,000.00
- QNCX N/A
- Revenue This Year
- GECC $32.54
- QNCX N/A
- Revenue Next Year
- GECC N/A
- QNCX N/A
- P/E Ratio
- GECC $25.68
- QNCX N/A
- Revenue Growth
- GECC 18.13
- QNCX N/A
- 52 Week Low
- GECC $8.87
- QNCX $0.51
- 52 Week High
- GECC $11.39
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- GECC 58.93
- QNCX 64.56
- Support Level
- GECC $10.28
- QNCX $1.43
- Resistance Level
- GECC $10.60
- QNCX $1.68
- Average True Range (ATR)
- GECC 0.25
- QNCX 0.14
- MACD
- GECC 0.02
- QNCX 0.02
- Stochastic Oscillator
- GECC 85.29
- QNCX 84.91
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.